83 related articles for article (PubMed ID: 18537959)
1. Exenatide may aggravate moderate diabetic renal impairment: a case report.
Johansen OE; Whitfield R
Br J Clin Pharmacol; 2008 Oct; 66(4):568-9. PubMed ID: 18537959
[No Abstract] [Full Text] [Related]
2. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
[No Abstract] [Full Text] [Related]
3. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
Charbonnel PB
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
[No Abstract] [Full Text] [Related]
4. Exenatide in type 2 diabetes.
Verzegnassi F; Chinello M
Lancet; 2010 Sep; 376(9746):1052-3; author reply 1053. PubMed ID: 20870094
[No Abstract] [Full Text] [Related]
5. Exenatide (Byetta) for type 2 diabetes.
Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
[TBL] [Abstract][Full Text] [Related]
6. Exenatide for once-weekly administration.
Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
8. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
López-Ruiz A; del Peso-Gilsanz C; Meoro-Avilés A; Soriano-Palao J; Andreu A; Cabezuelo J; Arias JL
Pharm World Sci; 2010 Oct; 32(5):559-61. PubMed ID: 20686848
[TBL] [Abstract][Full Text] [Related]
9. Exenatide once weekly in type 2 diabetes.
Scheen AJ
Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
[No Abstract] [Full Text] [Related]
10. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
Wenten M; Gaebler JA; Hussein M; Pelletier EM; Smith DB; Girase P; Noel RA; Braun DK; Bloomgren GL
Diabet Med; 2012 Nov; 29(11):1412-8. PubMed ID: 22416857
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
12. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
Wajcberg E; Tavaria A
Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187
[TBL] [Abstract][Full Text] [Related]
13. Exenatide-associated ischemic renal failure.
Weise WJ; Sivanandy MS; Block CA; Comi RJ
Diabetes Care; 2009 Feb; 32(2):e22-3. PubMed ID: 19171732
[No Abstract] [Full Text] [Related]
14. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
Nathan DM
Ann Intern Med; 2011 Jan; 154(2):131-2. PubMed ID: 21135287
[No Abstract] [Full Text] [Related]
15. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
16. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
17. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
[No Abstract] [Full Text] [Related]
18. Longacting exenatide in diabetes: DURATION-3.
Misra A; Joshi S
Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
[No Abstract] [Full Text] [Related]
19. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
Cohen D
BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395
[No Abstract] [Full Text] [Related]
20. Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.
Schwartz S
Curr Med Res Opin; 2008 Nov; 24(11):3009-22. PubMed ID: 18828960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
